scholarly journals The Diagnostic Value of Anti-Cyclic Citrullinated Peptide Antibodies (anti-CCP) in Patients with Rheumatoid Arthritis

2007 ◽  
Vol 26 (4) ◽  
pp. 285-288
Author(s):  
Ljubinka Damjanovska ◽  
Violeta Atanasovska ◽  
Todor Gruev
Keyword(s):  
Rheumatoid Arthritis ◽  
Diagnostic Value ◽  
Cross Sectional Study ◽  
Cross Sectional ◽  
Mean Values ◽  
Cyclic Citrullinated Peptide ◽  
The Mean ◽  
Citrullinated Peptide ◽  
Peptide Antibodies ◽  
Latex Test

The Diagnostic Value of Anti-Cyclic Citrullinated Peptide Antibodies (anti-CCP) in Patients with Rheumatoid ArthritisA cross-sectional study was carried out to analyze the prevalence of anti-CCP antibodies and IgM RF in the sera of 160 randomly selected patients from the Rheumatology Department: 60 with RA, 50 with other rheumatic diseases (non-RA), 50 healthy controls (HC). The mean age of the group was 50.06+/-11.9 years. There were 141 females (88.1%) and 19 males (11.9%). RA patients fulfilled the revised ACR criteria. The mean duration of the disease was 82.4 months. Anti-CCP ELISA kit and IgM RF Latex test were used. The mean anti-CCP values were as follows: RA 60.4+/-57.6, non-RA 2.1+/-3.6, HC 1.3 +/-0.4 U/mL. Respectively, the mean values of IgM RF were: RA 515.8+/-525, non-RA 102+/-294, HC 15+/-57.5. Forty out of 60 (66.6%) RA patients were anti-CCP positive. Forty one out of 60 (68.3%) RA patients were positive for IgM RF. As expected, anti-CCP showed comparable sensitivity (66.8% vs. 68.3%) and higher specificity (98% vs. 87%) than IgM RF, at optimal cut-off values. The presence of either anti-CCP or IgM RF increased the testing sensitivity for the diagnosis of RA to 76.6%. AUC was greater for anti-CCP than for IgM RF (0.92 vs. 0.82).

scholarly journals Diagnostic value of anti-cyclic citrullinated peptide antibodies in Greek patients with rheumatoid arthritis

2007 ◽  
Vol 8 (1) ◽  
Author(s):  
Ioannis Alexiou ◽  
Anastasios Germenis ◽  
Athanasios Ziogas ◽  
Katerina Theodoridou ◽  
Lazaros I Sakkas
Keyword(s):  
Rheumatoid Arthritis ◽  
Diagnostic Value ◽  
Cyclic Citrullinated Peptide ◽  
Citrullinated Peptide ◽  
Peptide Antibodies

High Levels of Anti-Cyclic Citrullinated Peptide Autoantibodies Are Associated with Co-occurrence of Pulmonary Diseases with Rheumatoid Arthritis

2011 ◽  
Vol 38 (6) ◽  
pp. 979-982 ◽  
Author(s):  
FLEUR AUBART ◽  
BRUNO CRESTANI ◽  
PASCALE NICAISE-ROLAND ◽  
FLORENCE TUBACH ◽  
CAROLINE BOLLET ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Risk Factors ◽  
Lung Disease ◽  
Cross Sectional Study ◽  
Cross Sectional ◽  
Cyclic Citrullinated Peptide ◽  
Independent Risk Factors ◽  
Male Sex ◽  
Citrullinated Peptide ◽  
Tomography Scan

Objective.To investigate whether levels of anti-cyclic citrullinated peptide antibodies (anti-CCP2) in patients with rheumatoid arthritis (RA) are associated with the co-occurrence of lung diseases.Methods.A total of 252 RA patients were included in a cross-sectional study. Pulmonary disease was confirmed by high-resolution chest computed tomography scan. Circulating anti-CCP2 were quantified using ELISA. Multivariate logistic regression was conducted to identify independent risk factors for lung disease.Results.Male sex (OR 3.29, 95% CI 1.59–6.80) and high anti-CCP2 levels (OR 1.49, 95% CI 1.25–1.78) were identified as independent risk factors for lung disease in the RA population.Conclusion.High anti-CCP2 levels are associated with lung disease in the RA population.

scholarly journals Anti-cyclic citrullinated peptide antibodies and rheumatoid factor in Rheumatoid Arthritis

2021 ◽  
Vol 106 (106(813)) ◽  
pp. 157-164
Author(s):  
R. Clavero-López ◽  
A.I. Navarro-Abad ◽  
M. Ruiz-Herance ◽  
J.M. Urra-Ardanaz
Keyword(s):  
Rheumatoid Arthritis ◽  
Rheumatoid Factor ◽  
Pharmacological Treatment ◽  
Test Validity ◽  
Reference Value ◽  
Diagnostic Value ◽  
Definitive Diagnosis ◽  
Cyclic Citrullinated Peptide ◽  
Citrullinated Peptide ◽  
Peptide Antibodies

Introduction: For the diagnosis of Rheumatoid Arthritis (RA), the detection of the autoantibodies, rheumatoid factor (FR) and cyclic citrullinated peptide antibodies (APCC) are used. The presence of these antibodies determines that the RA is classified as seropositive or seronegative, with important implications both in the clinical development and in the prognosis of the disease. Objective: To assess the role of APCC and RF in the diagnosis of RA, as well as its influence on the establishment of pharmacological treatment. Methodology: We studied 213 patients with initial clinical suspicion of RA and with determinations of FR and APCC. Their definitive diagnosis and the pharmacological treatment established were studied. Results: 63 of 213 patients had a definitive diagnosis of RA. 77.8% were classified as seropositive. The sensitivity and specificity were higher in the APCC compared to FR. Initially the RF presented a low diagnostic value since it was negative in more than two thirds of the patients with a diagnosis of RA. The precise adjustment of its reference value allowed its use as a useful diagnostic tool. The presence of antibodies in patients with RA influences the treatment of choice with an increased use of Methotrexate against other immunosuppressants in seropositive patients. Conclusions: The APCC presented better parameters of diagnostic test validity than the RF. The presence of antibodies in RA influences the treatment of choice possibly due to the greater severity of the pathology.

Sign in / Sign up

Export Citation Format

Share Document